Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Desnos-Ollivier, Marie; Moquet, Olivier; Chouaki, Taieb; Guérin, Anne-Marie; Dromer, Françoise

doi:10.1128/jcm.00325-11

Cited by 37Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal and yeast genetics research

Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Open access

Desnos-Ollivier, Marie, Moquet, Olivier, Chouaki, Taieb, Guérin, Anne-Marie, Dromer, Françoise·2011·Journal of Clinical Microbiology

DOI 10.1128/jcm.00325-11PMC PMC3122731

Open this paper in CoChat — free account

Abstract

Clavispora lusitaniae is an opportunistic human pathogen responsible for 0.6 to 2% of candidemia. This species is intrinsically susceptible to echinocandins. Nevertheless, in this study, development of echinocandin resistance in C. lusitaniae isolates was observed during caspofungin treatment. This resistance resulted from missense mutation in the echinocandin target Fks1 gene.

Integrity signals

Registry

Crossref · 10.1128/jcm.00325-11

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Echinocandin resistance has emerged in Candida over recent years.
“Echinocandin resistance has emerged over the recent years.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [14]
Echinocandin resistance has been found in most clinically relevant Candida species.
“It has been found in most clinically relevant Candida species, but is most common in C. glabrata with rates exceeding 10% at selected institutions.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [13]
Echinocandin resistance has been found in most clinically relevant Candida species.
“It has been found in most clinically relevant Candida species, but is most common in C. glabrata with rates exceeding 10% at selected institutions.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [14]
Echinocandin resistance has emerged in Candida over recent years.
“Echinocandin resistance has emerged over the recent years.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [13]
Most reports of acquired echinocandin resistance are case reports or case series, which collectively document the potential of resistance development in almost all species that are not intrinsically susceptible.
“Most are case reports or case series, which collectively document the potential of resistance development in almost all species that are not intrinsically susceptible (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [14]

Acquired echinocandin resistance has been reported in single isolates belonging to most Candida species including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis.
“Moreover, reports on acquired echinocandin resistance, defined as resistance among species that are normally susceptible, have emerged and today acquired resistance has been reported in single isolates belonging to most Candida species including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [13]
Acquired echinocandin resistance has been reported in single isolates belonging to most Candida species including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis.
“Moreover, reports on acquired echinocandin resistance, defined as resistance among species that are normally susceptible, have emerged and today acquired resistance has been reported in single isolates belonging to most Candida species including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [14]
Clinically relevant acquired echinocandin resistance in Candida has never been detected in the absence of FKS hot spot mutations.
“So far, clinically relevant acquired echinocandin resistance in Candida has never been detected in absence of FKS hot spot mutations.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [14]
Clinically relevant acquired echinocandin resistance in Candida has never been detected in the absence of FKS hot spot mutations.
“So far, clinically relevant acquired echinocandin resistance in Candida has never been detected in absence of FKS hot spot mutations.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [13]
Target gene sequencing has become increasingly available and appropriate primers have been designed and published for the most common species.
“Target gene sequencing has become increasingly available and appropriate primers designed and published for the most common species (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [14]

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2× · see citing works
“6 to 2% of the isolates recovered during candidemia (12, 18, 23).”
Background
Yeasts : characteristics and identification
Barnett, J. A., Payne, R. W., Yarrow, D., & Barnett, L. (2000) · Cited by 1,870 · see citing works
The Fungal Holomorph: Mitotic, Meiotic and Pleomorphic Speciation in Fungal Systematics
Reynolds, D. R., & Taylor, J. R. (1993) · Cited by 973 · see citing works
Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · see citing works
Fusarium and its near relatives
O’Donnell, K. (1993) · Medical Entomology and Zoology · Cited by 768 · see citing works
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 726 · see citing works
EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts
Rodríguez-Tudela, J. L., Arendrup, M. C., Barchiesi, F., Billé, J., Chryssanthou, E., Cuenca‐Estrella, M., Dannaoui, É., Denning, D. W., Donnelly, J. P., Dromer, F., et al. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01935.x · Cited by 651 · see citing works
Self-citation
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604 · see citing works
Molecular diagnostics of clinical strains of filamentous Basidiomycetes
de Hoog, S., & van den Ende, A. H. G. G. (1998) · Mycoses · doi:10.1111/j.1439-0507.1998.tb00321.x · Cited by 582 · see citing works
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · see citing works
Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434 · see citing works
Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients
Lortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362 · see citing works
Self-citation
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
Pfaller, M. A., Diekema, D. J., Andes, D. R., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M. R., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 335 · see citing works
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K. F., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311 · see citing works
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L., Smith, J. G., Pikounis, V. B., Balkovec, J. M., Bouffard, A., Dropinski, J. F., Rosen, H., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2333 · Cited by 241 · see citing works
Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1
Balashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225 · see citing works
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis
Laverdière, M., LALONDE, R. G., Baril, J.-G., Sheppard, D. C., Park, S., & Perlin, D. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl022 · Cited by 192 · see citing works
Phylogenetic relationships of human-pathogenicCladosporium(Xylohypha) species inferred from partial LS rRNA sequences
Masclaux, F., Guého, E., de Hoog, S., & Christen, R. (1995) · Medical Mycology · doi:10.1080/02681219580000651 · Cited by 187 · see citing works
One year prospective survey of Candida bloodstream infections in Scotland
Odds, F. C., Hanson, M. F., Davidson, A. D., Jacobsen, M. D., Wright, P., Whyte, J. A., Gow, N. A. R., & Jones, B. L. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47239-0 · Cited by 176 · see citing works
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., Jones, R. N., Turnidge, J. D., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01590-09 · Cited by 154 · see citing works
Acquired resistance to echinocandins in Candida albicans: case report and review
Baixench, M.-T., Aoun, N. B. T., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, É. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 149 · see citing works
Self-citation
Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing
Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-08 · Cited by 132 · see citing works
Self-citation
Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Kahn, J. N., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K. A., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-07 · Cited by 118 · see citing works
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
García‐Effrón, G., Chua, D. J., Tomada, J. R. T., DiPersio, J. R., Perlin, D. S., Ghannoum, M. A., & Bonilla, H. F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-09 · Cited by 104 · see citing works
Identification of Candida lusitaniae as an opportunistic yeast in humans
Holzschu, D. L., Presley, H. L., MIRANDA, M., & Phaff, H. J. (1979) · Journal of Clinical Microbiology · doi:10.1128/jcm.10.2.202-205.1979 · Cited by 80 · see citing works
Colony morphology switching of Candida lusitaniae and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature
Favel, A., Michel-Nguyen, A., Peyron, F., Martin, C., Thomachot, L., Datry, A., Bouchara, J., Challier, S., Noël, T., Chastin, C., et al. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(03)00094-4 · Cited by 67 · see citing works
Clavispora, a new yeast genus of the Saccharomycetales
de Miranda, L. R. (1979) · Antonie van Leeuwenhoek · doi:10.1007/bf00443285 · Cited by 51 · see citing works
Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniae
Florent, M., Noël, T., Ruprich‐Robert, G., Silva, B. D., Fitton‐Ouhabi, V., Chastin, C., Papon, N., & Chapeland‐Leclerc, F. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00880-08 · Cited by 50 · see citing works
Detection of Caspofungin Resistance in Candida spp. by Etest
Desnos‐Ollivier, M., Dromer, F., & Dannaoui, É. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00053-08 · Cited by 35 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008
Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101510 · Cited by 396 · see citing works
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299 · see citing works
Acquired multidrug antifungal resistance in Candida lusitaniae during therapy
Asner, S. A., Giulieri, S., Diezi, M., Marchetti, O., & Sanglard, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02204-15 · Cited by 82 · see citing works
Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria
Pfaller, M. A., Messer, S. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02481-13 · Cited by 74 · see citing works
Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae
Kannan, A., Asner, S. A., Trachsel, E., Kelly, S., Parker, J., & Sanglard, D. (2019) · mBio · doi:10.1128/mbio.02512-19 · Cited by 63 · see citing works
Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations
Desnos-Ollivier, M., Bretagne, S., Lortholary, O., Dromer, F., & the French Mycoses Study Group N. Brieu CH Aix, T. C. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01725-21 · Cited by 13 · see citing works
Self-citation

The Postantifungal and Paradoxical Effects of Echinocandins Against Candida spp.
Moriyama, B., Henning, S. A., Penzak, S. R., & Walsh, T. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.31 · Cited by 12 · see citing works
A comparative evaluation of properties and clinical efficacy of the echinocandins
Kim, R., Khachikian, D., & Reboli, A. C. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1479 · Cited by 48 · see citing works
The role of caspofungin and the echinocandins in the antifungal armamentarium.
Morrison, V. A. (2002) · PubMed · Cited by 15 · see citing works
Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
Tóth, Z., Forgács, L., Kardos, T., Kovács, R., Locke, J. B., Kardos, G., Nagy, F., Borman, A. M., Adnan, A., & Majoros, L. (2020) · Journal of Fungi · doi:10.3390/jof6030136 · Cited by 20 · see citing works
Echinocandin antifungals: review and update
Morrison, V. A. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.2.325 · Cited by 85 · see citing works

Authors: Desnos-Ollivier, M., Moquet, O., Chouaki, T., Guérin, A.-M., & Dromer, F.
Affiliations: Institut Pasteur, National Reference Center for Mycoses and Antifungals (NRCMA), Molecular Mycology Unit, Paris
Centre Hospitalier de Beauvais (FR)
Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire d'Amiens, Amiens
Service de Réanimation Polyvalente, Centre Hospitalier de Beauvais, Beauvais, France
Centre National de la Recherche Scientifique (FR)
ORCID: Moquet, Olivier
Dromer, Françoise
Venue: Journal of Clinical Microbiology
Publisher: American Society for Microbiology
Published: 2011-06
Volume: 49
Issue: 6
Pages: 2304-2306
ISSN: 0095-1137 (ISSN-L)
1098-660X
DOI: 10.1128/jcm.00325-11
PMC: PMC3122731
OpenAlex: W2112200434
Cited by: 37
References: 29
Citations by year: 2025: 3 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 3 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 5 · 2014: 3 · 2013: 2 · 2012: 1
FWCI: 1.29
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Journal of Clinical Microbiology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion, other-oa)
Funders: Institut de Veille Sanitaire
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords: Candida lusitaniae, echinocandin resistance, caspofungin, missense mutations, candidemia, antifungal resistance
MeSH terms: Caspofungin, Aged, Antifungal Agents, DNA Mutational Analysis, DNA, Fungal, Saccharomycetales, Glucosyltransferases, Humans, Male, Molecular Sequence Data, Mycoses, Sequence Analysis, DNA, Amino Acid Substitution, Mutation, Missense, Drug Resistance, Fungal, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks